SNDX · Syndax Pharmaceuticals, Inc.

The thesis

Syndax Pharmaceuticals still has a growing leukemia drug, Revuforj, but its shares have lost most of the support the prior note relied on. The Q3 2026 report, expected around 3 November 2026, shows whether Revuforj net revenue passed the $54.7 million reported for Q2.

The shares closed at $13.57 on 22 October 2026, 46.0% below the $25.15 52-week high and 33.9% lower over three months (adjusted daily closes). The fall followed the 12 October 2026 announcement that the Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis missed its primary endpoint. That close is also below the $15 level the prior note named as its invalidation, so the rating moves down to coverage without a pick.

The narrative is maturing and now carries a setback: the Revuforj launch figures of 4 August 2026 are well known, and the lung-disease failure of 12 October 2026 removed one expansion path for axatilimab.

Bullish and bearish views on Syndax Pharmaceuticals, Inc.

The bull case on Syndax Pharmaceuticals, Inc. (SNDX), in brief: Revuforj sales are still growing. The bear case: An expansion program failed.

Bull case

• Revuforj sales are still growing. Syndax reported Q2 2026 Revuforj net revenue of $54.7 million, up 91% from a year earlier and 12% from Q1 (Syndax Q2 results, 4 August 2026).
• The failed trial did not touch the marketed drugs. On 12 October 2026 Syndax said the MAXPIRe result does not affect ongoing axatilimab trials in other indications. The drug was well tolerated, with a safety profile similar to placebo.
• Frontline leukemia data are still guided. On 4 August 2026 Syndax said it expected further frontline BEAT AML and SAVE data in the second half of 2026.
• Analysts remain above the price. H.C. Wainwright reiterated a Buy rating with a $38 target on 13 October 2026. UBS had lowered its target to $33 from $37 and kept a Buy rating (reported 21 August 2026). Both sit well above the $13.57 close.

Bear case

• An expansion program failed. The 145-patient MAXPIRe trial did not meet its primary endpoint, the annualized rate of decline in forced vital capacity, and Syndax ended development in the disease (company release, 12 October 2026). Fierce Pharma reported the shares fell about 17% on the news.
• The price keeps breaking levels. The close of $13.57 on 22 October 2026 sits under the $17.09 low of 23 September 2026 and the $15 level named in the prior note. The 14-day relative strength index is 18.8, below the oversold line of 30.
• Analyst targets have drifted down. H.C. Wainwright's $38 target compares with the $41 reported by MarketBeat on 5 August 2026. UBS, JPMorgan, Citi and Baird were each reported by TheFly as lowering targets earlier in the autumn.
• Reported revenue is smaller than market sales. Incyte records Niktimvo net sales. Syndax books only its profit share, $18.1 million in Q2 2026, against $60.3 million of in-market sales.
• Development costs are rising. Q2 2026 research and development expense was $68.0 million versus $62.2 million a year earlier, tied mainly to frontline revumenib trials (Q2 results, 4 August 2026).

Price setup

The adjusted daily close on 22 October 2026 was $13.57. The 14-day relative strength index of 18.8 shows heavy selling over the past two weeks. Such readings sometimes precede short recoveries, and they do not show that selling has ended.

The $15 level and the $17.09 low of 23 September 2026 now act as resistance if the shares recover. No filing in the past two weeks changes the share count or the balance sheet.

Crowding evidence is thin. The shares sit well below their high, no wide gap above a rising average is visible, and no insider or issuance event has appeared in filings since the prior note. The one crowding item is the earnings date, due in roughly two weeks.

Catalysts, next 30 days

• Later in 2026: frontline BEAT AML and SAVE data, and the axatilimab chronic graft-versus-host disease readout. Syndax has not given dates for either. They fall outside the 30-day window unless announced earlier.

Elapsed catalysts

• ~3 November 2026 (est.): Q3 2026 financial results. Syndax has not confirmed the date; the Q3 2025 report came on 3 November 2025 after an announcement on 27 October 2025. Revuforj net revenue against $54.7 million is the main test, and the quarter's research spending shows the cost of the frontline trials. (passed 3d ago)

What would change the view

The case breaks if Q3 2026 Revuforj net revenue is at or below $54.7 million, because sequential growth would then have stalled. It also breaks on a daily close below $12, which would extend the post-trial-failure decline.

A Q3 report showing further Revuforj growth, together with frontline data supporting earlier-line use, would strengthen the case. A second missed endpoint in the remaining axatilimab trials would weaken it further.

What it trades with

The shares trade on company-specific results, not on a broad sector move. The 12 October 2026 trial failure drove the latest fall. Syndax's profit share depends on Incyte, which records Niktimvo sales, so Incyte's reporting and commercial execution feed directly into Syndax's collaboration revenue. Other mid-cap oncology and immunology developers react to the same clinical-trial and financing conditions, but no peer data point is cited here.